XASX
IME
Market cap11mUSD
Oct 07, Last price
0.30AUD
1D
0.00%
IPO
-100.00%
Name
ImExHS Ltd
Chart & performance
P/E
—
P/S
0.56
EPS
—
Div yield, %
—
Shrs. gr., 5y
15.55%
Rev. gr., 5y
21.56%
Revenues
29m
+9.04%
Net income
-3m
L+9.80%
CFO
565k
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
ImExHS Limited delivers cloud-powered medical imaging technologies to customers worldwide, including those in Australia. The firm specializes in the development and sale of modular imaging software systems, which encompass comprehensive information management platforms for disciplines such as radiology, cardiology, and pathology, alongside a robust picture archiving and communication system (PACS). Its principal software solutions include AQUILA for radiology, ALULA for pathology, and Antero for cardiology. Moreover, ImExHS offers STELLA.I, a suite of artificial intelligence tools hosted in the cloud, crafted to bolster diagnostic capabilities for medical professionals. The company further extends outsourced radiology and teleradiology services to hospitals and various other healthcare entities. Established in 2001, ImExHS Limited operates from its base in Mascot, Australia.
Key people
Non-Executive Chairman of the Board · since 2020
Chief Financial Officer, Company Secretary · since 2020
German Fumis
General Manager - Business Development · since 2020
Jorge Marin
ChiefMedical Officer · since 2018
Andres Vanegas
Chief Sales Officer · since 2018
Alejandro Varettoni
Chief Sales Officer - Latin America · since 2020
German Arango
Chief Executive Officer, Managing Director, Director · since 2018
Douglas Lingard
Non-Executive Director · since 2018
Non-Executive Director · since 2015
Carlos Jaime Palacio
Non-Executive Director · since 2020
Non-Executive Independent Director · since 2020
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||